AdjuTec Pharma AS

Antimicrobial Resistance at the Heart of EU’s Global Health Strategy

Oslo, Norway, 16 May 2023 – AdjuTec Pharma AS is a privately held company developing antibiotic resistance breakers.

The EU Council recommendation of 26 April urged members to step up EU actions to combat AMR. The Council recommendations cover multiple actions to be followed up and reported by the member countries within 4 years. These activities include supporting R&D of new treatments and improve market access.

From the Council recommendation:

“The Council welcomes the Commission’s intention to and Member States are invited to:

27. Support research and technological innovation for the detection, prevention and treatment of infections in humans caused by antimicrobial resistant pathogens, including the establishment of and significant investment in a European partnership to allow coordination, alignment and funding of cross-sectorial research and innovation on “One Health AMR”.

28. Promote the development of and accessibility to antimicrobials and other medical countermeasures relevant to combat AMR in humans, notably diagnostic tests and vaccines targeting antimicrobial resistant pathogens.

To that end, the Council welcomes the Commission’s intention to:

b. support research and development of AMR medical countermeasures, notably by coordinating funding of translational research and late-stage development of AMR medical countermeasures, including clinical trials for antimicrobials.“
"AMR has top priority at the EU Council and member states has to follow-up. Adjutec’s phase 1-ready product is in perfect position to deliver on this request. The company will apply for governmental to support our clinical program. Resistant bacteria require very high antibiotic doses that give patients severe side-effects. Our technology restores the effect of the antibiotics at hundred-fold lower doses and thereby reduces environmental spillage as well”, comments CEO Bjørn Klem
About antimicrobial resistance (AMR) –

AMR is a global health threat with an estimated 5mill associated deaths, including 1.27mill deaths attributable to bacterial AMR in 2019. WHO has declared that AMR is one of the top 10 global public health threats facing humanity. Misuse of antimicrobials is the main driver in the development of drug-resistant pathogens. AMR results in prolonged hospital stays at intensive care units with increased costs to the healthcare system. Without effective antimicrobials, the success of modern medicine in treating and preventing infections during major surgery and cancer chemotherapy, can be jeopardized.

About AdjuTec Pharma

AdjuTec Pharma is a company that is dedicated to developing and providing novel antibiotic resistance breakers to the global market. The company technology offers a unique mechanism of action that inactivates bacterial defence enzymes and restores bacterial sensitivity to antibiotics. The company’s lead product is APC148, a selective zinc chelator targeting bacterial metallo-ß-lactamase (MBL) enzymes. The technology was invented by Professor Pål Rongved and his group at the Department of Pharmacy, University of Oslo. The Company is located at St. Olavs gate 5, 0165 - downtown Oslo.

For more information, please visit

Please contact:

Follow us on LinkedIn and Twitter